Subsequently, a phase III study was published in August 2016, showing the results of OS, safety, immunogenicity, and serum EGF concentration of 405 stage IIIB/IV NSCLC patients post-CIMAvax-EGF vaccination [50]. This evidence concerns the gene EGF and non-small cell lung carcinoma.